A Cell Cycle Regulator Potentially Involved in Genesis of Many Tumor Types
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
A putative tumor suppressor locus on the short arm of human chromosome 9 has been localized to a region of less than 40 kilobases by means of homozygous deletions in melanoma cell lines. This region contained a gene, Multiple Tumor Suppressor 1 (MTS1), that encodes a previously identified inhibitor (p16) of cyclin-dependent kinase 4. MTS1 was homozygously deleted at high frequency in cell lines derived from tumors of lung, breast, brain, bone, skin, bladder, kidney, ovary, and lymphocyte. Melanoma cell lines that carried at least one copy of MTS1 frequently carried nonsense, missense, or frameshift mutations in the gene. These findings suggest that MTS1 mutations are involved in tumor formation in a wide range of tissues.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Within months of its discovery, the INK4a (CDKN2A) and the genetically linked INK4b gene (CDKN2B) (36) were implicated in a reverse genetic screen to play tumor suppressive roles in familial melanoma (37).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [37]
Citations
Cites
Molecular Cloning: A Laboratory Manual
Sambrook, J., Fritsch, E., & Maniatis, T. (1989) · UCLA - Biblioteca de Ciencias de la Salud · Cited by 133,589
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
p21 is a universal inhibitor of cyclin kinases
Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., & Beach, D. (1993) · Nature · doi:10.1038/366701a0 · Cited by 3,368
A novel cyclin encoded by a bcl1-linked candidate oncogene
Motokura, T., Bloom, T., Kim, H. G., Jüppner., H., Ruderman, J. V., Kronenberg, H. M., & Arnold, A. (1991) · Nature · doi:10.1038/350512a0 · Cited by 1,265
Functional interactions of the retinoblastoma protein with mammalian D-type cyclins
Ewen, M. E., Sluss, H. K., Sherr, C. J., Matsushime, H., Kato, J.-Y., & Livingston, D. M. (1993) · Cell · doi:10.1016/0092-8674(93)90136-e · Cited by 1,010
Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit
Gu, Y., Turck, C. W., & Morgan, D. O. (1993) · Nature · doi:10.1038/366707a0 · Cited by 764
p53: At the Crossroads of Molecular Carcinogenesis and Risk Sssessment
Harris, C. C. (1993) · Science · doi:10.1126/science.8266092 · Cited by 475
PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma.
Rosenberg, C. L., Wong, E., Petty, E. M., Bale, A. E., Tsujimoto, Y., Harris, N. L., & Arnold, A. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.21.9638 · Cited by 432
Research works printed but not linked: 1
- Weaver-Feldhaus, J., Proceedings of the National Academy of Sciences of the United States of America 91: 7563 (1994).
Cited by
Items 701–800 of 1,005
Frequent In activation of CDKN2A and Rare Mutation of TP53 in PCNSL
Cobbers, J. M. J. L., Wolter, M., REIFENBERGER, J., Ring, G. U., Jessen, F., An, H., Niederacher, D., Schmidt, E., Ichimura, K., Floeth, F. W., et al. (1998) · Brain Pathology · doi:10.1111/j.1750-3639.1998.tb00152.x · Cited by 82
Su, Y. A., Hutter, C. M., Trent, J. M., & Meltzer, P. S. (1996) · Molecular Carcinogenesis · doi:10.1002/(sici)1098-2744(199604)15:4<270::aid-mc4>3.0.co;2-k · Cited by 53
Tapper, J., Bützow, R. C., Wahlström, T., Seppälä, M. T., & Knuutila, S. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.304 · Cited by 75
“Given that homozygous deletions of this gene have been reported in ovarian carcinoma cell lines (Kamb et al, 1994), and loss of heterozygosity (LOH) of 9p has been found in ovarian tumours (Chenevix-Trench et al, 1994), our finding indicates that loss of this tumour-suppressor gene may not be…”
BackgroundMicro RNA ‐137 promoter methylation in oral lichen planus and oral squamous cell carcinoma
Dang, J., Bian, Y., Sun, J. Y., Chen, F., Dong, G., Liu, Q., Wang, X., Kjems, J., Gao, S., & Wang, Q. (2012) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.12012 · Cited by 74
p53 Rescue through HDM2 Antagonism Suppresses Melanoma Growth and Potentiates MEK Inhibition
Ji, Z., Njauw, C.-N. J., Taylor, M., Neel, V., Flaherty, K. T., & Tsao, H. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.313 · Cited by 78
Petronzelli, F., Sollima, D., Coppola, G., Martini‐Neri, M. E., Neri, G., & Genuardi, M. (2001) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.1159 · Cited by 75
“CDKN2A homozygous deletions are frequently observed in cell lines derived from several cancer types (Kamb et al., 1994), including glialcell nervous tumors (Jen et al., 1994; Perry et al., 1997), and appear to be involved in the malignant transformation of neurofibromas in patients affected with…”
BackgroundDriver Mutations in Melanoma: Lessons Learned From Bench-to-Bedside Studies
Mehnert, J. M., & Kluger, H. M. (2012) · Current Oncology Reports · doi:10.1007/s11912-012-0249-5 · Cited by 97
Obligate Roles for p16Ink4a and p19Arf-p53 in the Suppression of Murine Pancreatic Neoplasia
Bardeesy, N., Morgan, J., Sinha, M., Signoretti, S., Srivastava, S., Loda, M., Merlino, G., & DePinho, R. A. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.2.635-643.2002 · Cited by 74
“of human cell lines in vitro ( 22 , 25); conversely, this pathway is typically left intact in the immortalization of mouse embryonic fibroblasts.”
BackgroundBANDYOPADHYAY, D., & MEDRANO, E. E. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06637.x · Cited by 73
Incidence of p14ARF gene deletion in high-grade adult and pediatric astrocytomas
Newcomb, E. W., Alonso, M., Sung, T., & Miller, D. C. (2000) · Human Pathology · doi:10.1016/s0046-8177(00)80207-5 · Cited by 82
Cancer-associated mis-sense and deletion mutations impair p16INK4 CDK inhibitory activity
Lilischkis, R., Šarčević, B., Kennedy, C. J., Warlters, A., & Sutherland, R. L. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960410)66:2<249::aid-ijc19>3.0.co;2-7 · Cited by 81
Selective deletion of exon 1β of thep19ARF gene in metastatic melanoma cell lines
Kumar, R., Sauroja, I., Punnonen, K. R. A., Jansén, C. T., & Hemminki, K. (1998) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199811)23:3<273::aid-gcc11>3.0.co;2-n · Cited by 82
Huang, B., Han, W., Sheng, Z.-F., & Shen, G. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01271-2 · Cited by 84
How do mutated oncogenes and tumor suppressor genes cause cancer?
Grandér, D. (1998) · Medical Oncology · doi:10.1007/bf02787340 · Cited by 92
González, M. V., Pello, M. F., López‐Larrea, C., Suarez, C. M., Menéndez, M., & Coto, E. (1995) · PubMed · Cited by 82
Esophageal cancer surgery: The value of controlled clinical trials
Law, S. Y.-K., & Wong, J. (1997) · Seminars in Surgical Oncology · doi:10.1002/(sici)1098-2388(199707/08)13:4<270::aid-ssu9>3.0.co;2-2 · Cited by 8
Hoos, A., Hepp, H. H., Kaul, S., Ahlert, T., Bastert, G., & Wallwiener, D. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980220)79:1<8::aid-ijc2>3.0.co;2-5 · Cited by 72
Dolznig, H., Bartůněk, P., Nasmyth, K., Müllner, E. W., & Beug, H. (1995) · PubMed · Cited by 93
Bellmunt, J., Ribas, A., Eres, N., Albanell, J., Almanza, C., Bermejo, B., Sol�, L.-A., & Baselga, J. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19971115)80:10<1966::aid-cncr14>3.0.co;2-w · Cited by 228
Okamoto, A., Jiang, W. B., Kim, S. J., Spillare, E. A., Stoner, G. D., Weinstein, I. B., & Harris, C. C. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.24.11576 · Cited by 76
Serological evidence of an association betweenChlamydia pneumoniae infection and lung cancer
Laurila, A. L., Anttila, T., Läärä, E., Bloigu, A., Virtamo, J., Albanes, D., Leinonen, M., & Saikku, P. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970220)74:1<31::aid-ijc6>3.0.co;2-1 · Cited by 138
Molecular Biological Determinations of Meningioma Progression and Recurrence
Linsler, S., Kraemer, D., Drieß, C., Oertel, J., Kammers, K., Rahnenführer, J., Ketter, R., & Urbschat, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094987 · Cited by 75
Chemoṕrevention of human cancer: biology and therapy
Tanaka, T. (1997) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(97)00232-1 · Cited by 79
Recurrent Patterns of Dual RB and p53 Pathway Inactivation in Melanoma
Yang, G., Rajadurai, A., & Tsao, H. (2005) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2005.23931.x · Cited by 81
“Melanoma cell lines have led to the discovery of many key melanoma loci to date including CDKN2A”
BackgroundDNA damage, p14ARF, Nucleophosmin (NPM/B23), and cancer
Gjerset, R. A. (2006) · Journal of Molecular Histology · doi:10.1007/s10735-006-9040-y · Cited by 87
Biden, K. G., Young, J. P., Buttenshaw, R. L., Searle, J. W., Cooksley, G., Xu, D., & Leggett, B. (1997) · Hepatology · doi:10.1002/hep.510250317 · Cited by 72
Contribution of Germline Mutations in BRCA2 , P16 INK4A , P14 ARF and P15 to Uveal Melanoma
Hearle, N., Damato, B. E., Humphreys, J., Wixey, J., Green, H. E., Stone, J. G., Easton, D. F., & Houlston, R. S. (2003) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.02-0026 · Cited by 72
Habuchi, T., Yoshida, O., & Knowles, M. A. (1997) · Human Molecular Genetics · doi:10.1093/hmg/6.6.913 · Cited by 77
Clinic-based study of plexiform neurofibromas in neurofibromatosis 1
Waggoner, D. J., Towbin, J., Gottesman, G., & Gutmann, D. H. (2000) · American Journal of Medical Genetics · doi:10.1002/(sici)1096-8628(20000515)92:2<132::aid-ajmg10>3.0.co;2-6 · Cited by 130
Musgrove, E. A., Liuschkis, R., Cornish, A. L., Lee, C. S. L., Setlur, V., Seshadri, R., & Sutherland, R. L. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910630420 · Cited by 71
Molecular Pathogenesis of Aids-Related Lymphomas
Gaïdano, G., & Dalla‐Favera, R. (1995) · Advances in cancer research · doi:10.1016/s0065-230x(08)60712-5 · Cited by 74
Schmidt, E., Ichimura, K., Messerle, K. R., Goike, H., & Collins, V. P. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.2 · Cited by 77
Inactivation of Tumor Suppressor Genes p15INK4b and p16INK4a in Primary Cutaneous B Cell Lymphoma
Child, F. J., Scarisbrick, J. J., Russell‐Jones, R., Whittaker, S. J., Calonje, E. J., & Orchard, G. E. (2002) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2002.01785.x · Cited by 72
CDKN2a/p16INK4a Mutations and Lack of p19ARF Involvement in Familial Melanoma Kindreds
Fargnoli, M. C., Chimenti, S., Peris, K., Keller, G., Soyer, H. P., Pozzo, V. D., & Höfler, H. (1998) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.1998.00412.x · Cited by 80
Mulligan, G. J., Wong, J., & Jacks, T. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.1.206 · Cited by 72
“Indeed, mutation of p16 is detected in a wider spectrum of human tumors than that of RB and also appears to occur more frequently in several tumor types (1, 3, 26, 38, 54, 75).”
BackgroundMTS1/p16/CDKN2 lesions in primary glioblastoma multiforme.
Moulton, T. A., Samara, G., Chung, W., Yuan, L., Desai, R. D., Sisti, M. B., Bruce, J., & Tycko, B. (1995) · PubMed · Cited by 86
Khanna, C., Anderson, P. M., Hasz, D. E., Katsanis, E., Neville, M., & Klausner, J. S. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970401)79:7 · Cited by 561
A minimum folding unit in the ankyrin repeat protein p16 INK4 1 1Edited by C. R. Matthews
Zhang, B., & Peng, Z. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.3803 · Cited by 77
Matsuda, Y. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.1734 · Cited by 87
“FREQUENT INACTIVATION OF p16 IN HCC p 1 6 i s a s p e c i f i c i n h i b i t o r o f C D K 4 a n d C D K 6 and potentially blocks G1 cell-cycle progression via dephosphorylation of Rb through its inhibitory effect on CDK4/cyclin D1 complex activity[9, 10 ].”
BackgroundTakemoto, S., Trovato, R., Cereseto, A., Nicot, C., Kislyakova, T., Casareto, L., Waldmann, T. A., Torelli, G., & Franchini, G. (2000) · Blood · doi:10.1182/blood.v95.12.3939 · Cited by 74
Alterations of INK4A and INK4B Genes in Adult Soft Tissue Sarcomas: Effect on Survival
Orlow, I., Drobnjak, M., Zhang, Z.-F., Lewis, J., Woodruff, J. M., Brennan, M. F., & Cordon-Cardo, C. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.1.73 · Cited by 71
Changing patterns in the incidence of esophageal and gastric carcinoma in the United States
Devesa, S. S., Blot, W. J., & Fraumeni, J. F. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981115)83:10<2099::aid-cncr8>3.0.co;2-3 · Cited by 2,101
Smith‐Sørensen, B., Lind, G. E., Skotheim, R. I., Fosså, S. D., Fodstad, Ø., Stenwig, A., Jakobsen, K. S., & Lothe, R. A. (2002) · Oncogene · doi:10.1038/sj.onc.1205978 · Cited by 82
“The CDKN2A gene maps to 9p21 (Kamb et al., 1994; Nobori et al., 1994), and loss of heterozygosity at 9p21 loci, implying loss of one CDKN2A allele, has been reported for TGCT (Heidenreich et al., 1998; Murty et al., 1994).”
Backgroundp16INK4A and p15INK4B gene deletions in primary leukemias
Haidar, M., Cao, X., Manshouri, T., Chan, L., Glassman, A., Kantarjian, H., Keating, M., Beran, M., & Albitar, M. (1995) · Blood · doi:10.1182/blood.v86.1.311.bloodjournal861311 · Cited by 71
Ras Activation in Astrocytomas and Neurofibromas
Guha, A. (1998) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100034272 · Cited by 76
Tokino, T., Urano, T., Furuhata, T., Matsushima, M., Miyatsu, T., Sasaki, S., & Nakamura, Y. (1996) · Human Genetics · doi:10.1007/bf02281873 · Cited by 77
ARF Differentially Modulates Apoptosis Induced by E2F1 and Myc
Russell, J. L., Powers, J. T., Rounbehler, R. J., Rogers, P. M., Conti, C. J., & Johnson, D. G. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.5.1360-1368.2002 · Cited by 71
“ARF (p19 in mice, p14 in humans) is one of two tumor suppressors encoded at the INK4a locus, a chromosomal region frequently deleted in human tumors (21, 23, 36, 46).”
BackgroundLi, W., Liu, D., Tang, S., Li, D., Han, R., Tian, Y., Li, H., Li, G., Li, W., Liu, X., et al. (2018) · Poultry Science · doi:10.3382/ps/pey404 · Cited by 70
The Renaissance of Cyclin Dependent Kinase Inhibitors
Ettl, T., Schulz, D., & Bauer, R. J. (2022) · Cancers · doi:10.3390/cancers14020293 · Cited by 76
“In HPV-positive HNSCC, the viral oncogenes E6 and E7 are associated with reduced pRb and p16INK4a overexpression.”
BackgroundInfluentialFu, L., Dong, S.-S., Xie, Y.-W., Tai, L.-S., Chen, L., Kong, K. L., Man, K., Xie, D., Li, Y., Cheng, Y., et al. (2010) · Hepatology · doi:10.1002/hep.23540 · Cited by 70
Dietary fat intake and risk of prostate cancer: A prospective study of 25,708 Norwegian men
Veierød, M. B., Laake, P., & Thelle, D. S. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19971127)73:5<634::aid-ijc4>3.0.co;2-y · Cited by 206
Box, A. H., & Demetrick, D. J. (2004) · Carcinogenesis · doi:10.1093/carcin/bgh274 · Cited by 81
Mueller, A., Odze, R. D., Jenkins, T. D., Shahsesfaei, A., Nakagawa, H., Inomoto, T., & Rustgi, A. K. (1997) · PubMed · Cited by 70
Rodeck, U., Nishiyama, T., & Mauviel, A. (1999) · PubMed · Cited by 70
Gotoh, A., Kao, C. H., Ko, S.-C., Hamada, K., Liu, T.-J., & Chung, L. W. K. (1997) · The Journal of Urology · doi:10.1016/s0022-5347(01)64574-9 · Cited by 77
Molecular processes of chromosome 9p21 deletions in human cancers
Sasaki, S., Kitagawa, Y., Sekido, Y., Minna, J. D., Kuwano, H., Yokota, J., & Kohno, T. (2003) · Oncogene · doi:10.1038/sj.onc.1206589 · Cited by 75
“All these cell lines have been shown to have homozygous 9p21 deletions (Kamb et al., 1994; Nobori et al., 1994; Tanaka et al., 1997; Hamada et al., 1998, 2000; Kohno, unpublished data) (Table 1).”
BackgroundYang, P., Ma, J., Zhang, B., Duan, H., He, Z., Zeng, J.-L., Zeng, X., Li, D., Wang, Q., Xiao, Y., et al. (2012) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-11-0784 · Cited by 79
“60% to 70% in primary lung cancers (10) with low frequency of mutations (16).”
BackgroundLatil, A., Bièche, I., Chêne, L., Laurendeau, I., Berthon, P., Cussenot, O., & Vidaud, M. (2003) · PubMed · Cited by 69
Takeuchi, H., Ozawa, S., Ando, N., Shih, C.-H., Koyanagi, K., Ueda, M., & Kitajima, M. (1997) · PubMed · Cited by 69
Alterations of Rb, p16INK4A and cyclin D1 in the tumorigenesis of oral squamous cell carcinomas
Nakahara, Y., Shintani, S., Mihara, M., Kiyota, A., Ueyama, Y., & Matsumura, T. (2000) · Cancer Letters · doi:10.1016/s0304-3835(00)00546-2 · Cited by 71
Chromosome 18q allelic loss and prognosis in stage II and III colon cancer
Lanza, G., Matteuzzi, M., Gafá, R., Orvieto, E., Maestri, I., Santini, A., & del Senno, L. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980821)79:4<390::aid-ijc14>3.0.co;2-9 · Cited by 141
Leong, S. M., Tan, B. X., Ahmad, B., Yan, T., Chee, L. Y., Ang, S. T., Tay, K.-G., Koh, L. P., Yeoh, A. E. J., Koay, E. S.-C., et al. (2010) · Blood · doi:10.1182/blood-2009-12-256149 · Cited by 68
Nakahara, Y., Shintani, S., Mihara, M., Ueyama, Y., & Matsumura, T. (2001) · Cancer Letters · doi:10.1016/s0304-3835(00)00699-6 · Cited by 71
Almohanna, M., Manogaran, P. S., AL‐MUKHALAFI, Z., Al‐Hussein, K., & Aboussekhra, A. (2004) · Oncogene · doi:10.1038/sj.onc.1206927 · Cited by 81
“p16 is a key tumor-suppressor gene product that blocks the progression of the cell cycle by binding to either CDK4 or CDK6 and inhibiting the action of cyclin D (Serrano et al., 1993; Kamb et al., 1994; Nobori et al., 1994; Ortega et al., 2002).”
BackgroundSporadic multiple primary melanoma cases: CDKN2A germline mutations with a founder effect
Auroy, S., Avril, M., Chompret, A., Pham, D., Goldstein, A. M., Bianchi‐Scarrà, G., Frébourg, T., Joly, P., Spatz, A., Rubino, C., et al. (2001) · Genes Chromosomes and Cancer · doi:10.1002/gcc.1183 · Cited by 72
Review of allelic loss and gain in prostate cancer
Bova, G. S., & Isaacs, W. B. (1996) · World Journal of Urology · doi:10.1007/bf00184607 · Cited by 68
Regulation of apoptosis in immune cells
Mountz, J. D., Zhou, T., Wu, J., Wang, W., Su, X., & Cheng, J. (1995) · Journal of Clinical Immunology · doi:10.1007/bf01489485 · Cited by 68
“Some cyclin-dependent inhibitors are specific for single cyclin-dependent kinases, pl6 binds only to CDK4 and has identified as a potent tumor suppressor protein that is deleted in certain types of tumors (46, 47).”
BackgroundÄssämäki, R., Sarlomo‐Rikala, M., López‐Guerrero, J. A., Lasota, J. P., Andersson, L. C., Llombart‐Bosch, A., Miettinen, M., & Knuutila, S. (2007) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20439 · Cited by 67
“Together these three tumor suppressors regulate two important cell cycle checkpoints and the loss of these genes can lead to replicative senescence, cell immortalization, and tumor generation (Serrano et al., 1993; Hannon and Beach, 1994; Kamb et al., 1994; Enders, 2003).”
BackgroundKubo, A., Nakagawa, K., Varma, R. K., Conrad, N. K., Cheng, J. Q., Lee, W. C., Testa, J. R., Johnson, B. E., Kaye, F. J., & Kelley, M. J. (1999) · PubMed · Cited by 81
Ried, T., Knutzen, R., Steinbeck, R., Blegen, H., Schröck, E., Heselmeyer, K., du Manoir, S., & Auer, G. (1996) · Genes, Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199604)15:4<234::aid-gcc5>3.0.co;2-2 · Cited by 404
Simons, A., Schepens, M. T., Jeuken, J. W. M., Sprenger, S. H. E., van de Zande, G., Bjerkehagen, B., Forus, A., Weibolt, V., Molenaar, I., van den Berg, E., et al. (2000) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(99)00178-8 · Cited by 67
Disturbance of neuronal plasticity is a critical pathogenetic event in Alzheimer's disease
Arendt, T. (2001) · International Journal of Developmental Neuroscience · doi:10.1016/s0736-5748(01)00007-7 · Cited by 67
Germline CDKN2A mutation implicated in predisposition to multiple myeloma
Dilworth, D., Liu, L., Stewart, A. K., Berenson, J. R., Lassam, N. J., & Hogg, D. (2000) · Blood · doi:10.1182/blood.v95.5.1869.005k09_1869_1871 · Cited by 67
Liu, P. P., Wijmenga, C., Hajra, A. K., Blake, T. B., Kelley, C. A., Adelstein, R. S., Bagg, A., Rector, J. T., Cotelingam, J. D., Willman, C. L., et al. (1996) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199606)16:2<77::aid-gcc1>3.0.co;2-# · Cited by 73
Visualization of INT2 and HST1 Amplification in oral squamous cell carcinomas
Lese, C. M., ROSSIE, K. M., Appel, B. N., Reddy, J. K., Johnson, J. T., Myers, E. N., & Gollin, S. M. (1995) · Genes Chromosomes and Cancer · doi:10.1002/gcc.2870120409 · Cited by 67
Molecular Genetics of Exocrine Pancreatic Neoplasms
Hahn, S. A., & Kern, S. E. (1995) · Surgical Clinics of North America · doi:10.1016/s0039-6109(16)46732-0 · Cited by 72
Cyclin-dependent kinases: regulators of the cell cycle and more
Murray, A. W. (1994) · Chemistry & Biology · doi:10.1016/1074-5521(94)90009-4 · Cited by 66
Waring, A., Takata, M., Rehman, I., & Rees, J. L. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.113 · Cited by 67
High Frequency of p16 Promoter Methylation in NRAS-Mutated Cutaneous Melanoma
Jonsson, A., Tuominen, R., Grafström, E., Hansson, J., & Egyházi, S. (2010) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.216 · Cited by 73
Zhou, C., Shen, Z., Ye, D., Li, Q., Deng, H., Liu, H., & Li, J. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000494473 · Cited by 70
Role of p53 and Rb in Ovarian Cancer
Corney, D. C., Flesken‐Nikitin, A., Choi, J., & Nikitin, A. Y. (2008) · Springer eBooks · doi:10.1007/978-0-387-68969-2_9 · Cited by 78
“2/7 (29) (Kamb et al., 1994) 1/50 (2) (Brown et al., 2001) 2/27 (7) (Wong et al., 1997) 2/70 (3) (Fujita et al., 1997) 2/88 (2) (Shih Ie and Kurman, 2004) 5/30 (17) (Kanuma et al., 1997) 0/22 (0) (Shigemasa et al., 1997) 1/94 (1) (Milde-Langosch et al., 1998) 0/23 (0) (Niederacher et al., 1999)…”
Thompson, P. M., Maris, J. M., Hogarty, M. D., Seeger, R. C., Reynolds, C. P., Brodeur, G. M., & White, P. S. (2001) · PubMed · Cited by 73
Sawyer, T. K. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.1.1 · Cited by 69
Labuhn, M., Jones, G., Speel, E. M., Maier, D., Zweifel, C., Gratzl, O., Meir, E. G. V., Hegi, M. E., & Merlo, A. (2001) · Oncogene · doi:10.1038/sj.onc.1204197 · Cited by 75
“Exons 1a, 2 and 3 encode p16INK4A which has been established as a tumor suppressor gene in human cancer (Cairns et al., 1995; Kamb et al., 1994; Nobori et al., 1994).”
BackgroundSmith, R. C., Wills, K. N., Antelman, D., Perlman, H., Truong, L. N., Krasinski, K. L., & Walsh, K. X. (1997) · Circulation · doi:10.1161/01.cir.96.6.1899 · Cited by 70
Guo, L., Wang, Z., Du, Y., Mao, J., Zhang, J., Yu, Z., Guo, J., Zhao, J., Zhou, H., Wang, H., et al. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01274-z · Cited by 75
“ramarkbaly related to the occurrence of liver cancer [10, 22].”
BackgroundGiglio, S., Cirombella, R., Amodeo, R., Portaro, L., Lavra, L., & Vecchione, A. M. (2013) · Journal of Cellular Physiology · doi:10.1002/jcp.24368 · Cited by 66
Csepregi, A., Ebert, M. P., Röcken, C., Schneider‐Stock, R., Hoffmann, J., Schulz, H., Roessner, A., & Malfertheiner, P. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-317 · Cited by 68
“CDKN2A is regarded as tumour suppressor gene because it is frequently silenced by deletion or inactivating mutation in human cancers [7-9].”
BackgroundTumor suppressor gene methylation in follicular lymphoma: a comprehensive review.
Hayslip, J. W., & Montero, A. J. (2006) · Molecular Cancer · doi:10.1186/1476-4598-5-44 · Cited by 76
“p15 inhibits cyclin dependent kinases 4 and 6 contributing to cell cycle arrest at the G1-S transition [30].”
Yoshiji, H., Harris, S. R., Raso, E., Gomez, D. E., Lindsay, C. K., Shibuya, M., Sinha, C. C., & Thorgeirsson, U. P. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980105)75:1<81::aid-ijc13>3.0.co;2-g · Cited by 119
Selected Novel Anticancer Treatments Targeting Cell Signaling Proteins
Elsayed, Y. A., & Sausville, E. A. (2001) · The Oncologist · doi:10.1634/theoncologist.6-6-517 · Cited by 79
P 16 Overexpression: A potential early indicator of transformation in ovarian carcinoma
Shigemasa, K., Hu, C., WEST, C., CLARKE, J., Parham, G. P., Parmley, T. H., Korourian, S., Baker, V. V., & OBRIEN, T. (1997) · Journal of the Society for Gynecologic Investigation · doi:10.1016/s1071-5576(97)81110-0 · Cited by 64
Morita, R., Fujimoto, A., Hatta, N., Takehara, K., & Takata, M. (1998) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.1998.00458.x · Cited by 65
DNA Replication of First-Generation Adenovirus Vectors in Tumor Cells
Steinwaerder, D. S., Carlson, C. A., & Lieber, A. (2000) · Human Gene Therapy · doi:10.1089/10430340050129549 · Cited by 73
“Another common defect observed in many different tumors is the loss of control of the G 1 -to-S transition due to mutation or inactivation of pRb or p16, a kinase inhibitor that regulates the phosphorylation and activity of pRb (Kamb et al., 1994; Okamoto et al., 1994; Winberg, 1995).”
High Frequency of Allelic Loss in Dysplastic Lichenoid Lesions
Zhang, L., Cheng, X., Li, Y.-H., Poh, C. F.-Y., Zeng, T., Priddy, R., Lovas, J. G. L., Freedman, P. D., Daley, T. D., & Rosin, M. P. (2000) · Laboratory Investigation · doi:10.1038/labinvest.3780026 · Cited by 64
“The 9p21 locus has been linked to a putative tumor suppressor p16INK4A, a gene that codes for a cyclin-dependent kinase inhibitor involved in regulation of the cell cycle (Kamb et al, 1994).”
BackgroundManagement of familial melanoma
Newton‐Bishop, J., Harland, M., Randerson‐Moor, J. A., & Bishop, D. T. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)71010-5 · Cited by 79
Isolation and Characterization of a Novel Pituitary Tumor Apoptosis Gene
Bahar, A., Simpson, D. J. W., Cutty, S. J., Bicknell, J., Hoban, P. R., Holley, S. L., Mourtada‐Maarabouni, M., Williams, G. T., Clayton, R. N., & Farrell, W. E. (2004) · Molecular Endocrinology · doi:10.1210/me.2004-0087 · Cited by 64
Melanoma: Where we are and where we go
Mohammadpour, A., Derakhshan, M., Darabi, H., Hedayat, P., & Momeni, M. R. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27286 · Cited by 72
“…amplified Curtin et al. (2005) and Sauter et al. (2002) BRAF 50–70% mutated Davies et al. (2002) INK4A 40–87% mutated, deleted Bartkova et al. (1996) and Kamb et al. (1994) CDK4 4% mutated Curtin et al. (2005) and Stark and Hayward (2007) PTEN 5–20% deleted or mutated Tsao et al. (2004) and Wu et…”
BackgroundRegulation of Tumor Suppressor Gene CDKN2A and Encoded p16-INK4a Protein by Covalent Modifications
Jiao, Y., Feng, Y., & Wang, X. (2018) · Biochemistry (Moscow) · doi:10.1134/s0006297918110019 · Cited by 81
Molecular aberrations of the G1-S checkpoint in myxoid and round cell liposarcoma.
Tos, A. P. D., Piccinin, S., Doglioni, C., Vukosavljevic, T., Mentzel, T., Boiocchi, M., & Fletcher, C. D. �. (1997) · Europe PMC (PubMed Central) · Cited by 64
Metadata
- Authors
- Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., & Skolnick, M. H.
- Affiliations
- Myriad Genetics (US)
- Memorial Sloan Kettering Cancer Center (US)
- Cross Cancer Institute (CA)
- National Institutes of Health (US)
- University of Utah (US)
- Venue
- Science
- Published
- 1994-04-15
- Volume
- 264
- Issue
- 5157
- Pages
- 436-440
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1983348452
- Cited by
- 2,751
- References
- 26
- Citations by year
- 2026: 11 · 2025: 8 · 2024: 18 · 2023: 12 · 2022: 22 · 2021: 31 · 2020: 24 · 2019: 23 · 2018: 34 · 2017: 45 · 2016: 20 · 2015: 32 · 2014: 31 · 2013: 44 · 2012: 54
- FWCI
- 115.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p01ca048711-05)
- National Cancer Institute (CA 48711)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- CDKN2A, p16, tumor suppressor, chromosome 9p, homozygous deletion, melanoma cell lines, CDK4, cell cycle regulation, genetic mutations
- MeSH terms
- Base Sequence, Carrier Proteins, Cell Cycle, Chromosomes, Human, Pair 9, Cosmids, Exons, Humans, Introns, Melanoma, Molecular Sequence Data, Mutation, Neoplasms, Proto-Oncogene Proteins, Tumor Cells, Cultured, Genes, Tumor Suppressor, Gene Deletion, Cyclin-Dependent Kinases, Cyclin-Dependent Kinase Inhibitor p16, Protein Kinase Inhibitors, Cyclin-Dependent Kinase 4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.